Business Wire

Colt harnesses ADVA FSP 3000 for quantum-secured transport in live network trial

16.2.2021 11:00:00 EET | Business Wire | Press release

Share

ADVA (FSE: ADV) today announced that Colt Technology Services has successfully conducted a field trial of quantum-secured transport using its FSP 3000 platform with ConnectGuard™ Layer 1 encryption technology. The trial utilized quantum key distribution (QKD) to super-encrypt live data traffic, demonstrating how mission-critical services can be protected even against large-scale attacks. Conducted over Colt’s deployed metro network in Frankfurt, the demo shows how enterprise customers can achieve secure cloud access and robustly protect sensitive data in the long term. ADVA’s partner ID Quantique also played a key role in the trial.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210216005179/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

ADVA’s ConnectGuard™ technology helps Colt showcase the future of quantum-safe networking (Photo: Business Wire)

“With quantum computers on the horizon, it’s crucial to stay one step ahead of the hackers. This trial is a major step towards the next generation of cryptographic infrastructure and takes us closer to safeguarding our customers’ information from tomorrow’s threats,” said Oktay Tekin, director, sales engineers, DACH, Colt Technology Services. “Businesses across the world depend on the speed, reliability and robust security of our services to operate effectively and with complete peace of mind. By conducting this trial with ADVA to harness QKD technologies, we’re exploring how to protect against unprecedented challenges further down the line.”

Widely predicted to be vital to the future of network security, QKD offers the ultimate defense against eavesdropping attacks. Using the laws of physics to create tamper-proof encryption keys, it protects traffic from all threats, including data harvesting for future quantum hacking. Colt’s trial harnessed the ADVA FSP 3000, which receives quantum keys generated by ID Quantique’s QKD technology. The QKD provides quantum random bit strings. These keys are used as an additional entropy source for the ADVA encryption solution, operating at line speeds of 100Gbit/s. The solution is the first commercial high-speed optical networking product to feature a dedicated interface for quantum keys based on the ETSI key delivery standard.

“Our FSP 3000 ConnectGuard™ encryption solution ensures maximum security as well as high capacity and low latency. In recent years, it has won a fierce reputation for protecting service provider and enterprise networks across the globe. Now, this trial of QKD-secure transport is proving how vital our technology will be even in the post-quantum era,” commented Uli Schlegel, director, product line management, ADVA. “Colt’s trial shows that it’s now possible to secure high-speed connectivity over deployed operational networks against tomorrow’s quantum computer attacks. It’s a significant milestone for Colt’s enterprise customers. From sensitive financial information to valuable intellectual property, their data will soon be shielded from the cybercriminals of the future.”


About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.

About Colt
Colt strives to transform the way the world works through the power of connectivity - taking what’s always been in its DNA to enable customers’ success. The Colt IQ Network connects more than 900+ data centres and over 29,000 on net buildings across Europe, Asia and North America’s largest business hubs. Colt understands today’s shifting connectivity requirements and provides agile, on-demand and secure high bandwidth networking and voice solutions to ensure enterprises can thrive. Customers include data-intensive organisations spanning over 210 cities in more than 30 countries. Colt is a recognised innovator and pioneer in Software Defined Networks (SDN) and Network Function Virtualisation (NFV). Privately owned, Colt is one of the most financially sound companies in the sector, and because of this, it’s able to put its customers’ needs at its core. For more information, please visit www.colt.net.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vena Completes Acterys Acquisition to Accelerate Orchestrated Planning for the Microsoft Ecosystem26.3.2026 15:00:00 EET | Press release

Vena, the AI-powered Orchestrated Performance Management platform purpose-built to fully amplify the Microsoft technology ecosystem, today announced it has completed its acquisition of Acterys, the leading Microsoft Power BI–based operational planning and app development platform. The move strengthens Vena’s Orchestrated Planning solution and begins phased integration of the two platforms. Modern enterprises are struggling to keep up with the volatility and dynamism of the markets they serve. Market drivers and signals shift rapidly, and the ability to assess, plan and execute with confidence and speed is more important than ever. These forces, combined with overwhelming data density and disparity, have created a new constraint: decision latency—the time between signal and action. As that gap widens, confidence erodes and competitive advantage is lost. Orchestrated Planning removes decision latency by harmonizing data, people, processes and agentic capabilities to help organizations mo

Nearly Half of Global C-Suites Plan U.S. Expansion Within 12 Months, as Supply Chain and Capital Access Drive Growth26.3.2026 15:00:00 EET | Press release

Nearly half (45%) of global C-suite leaders plan to establish a legal entity in the United States within the next 12 months, highlighting continued demand for access to the U.S. market. This finding from the latest research by CSC—the leading provider of global business administration and compliance solutions—demonstrates the U.S. continues to attract investment from around the world, even as companies face an increasingly complex regulatory landscape. CSC surveyed 300 C-level executives at large organizations headquartered in Europe, the U.K., Asia Pacific, and South America to examine global sentiment toward U.S. market entry, including expansion plans, strategic drivers, and regulatory challenges.1 CSC’s report Navigating U.S. Market Entry: Insights, Risks, and Opportunities for Global Businesses details the results. The research highlights strong forward momentum toward U.S. expansion. In addition to the 45% planning to establish an entity within the next 12 months, a further 27% s

Rubedo Life Sciences Announces Positive Preliminary Phase 1 Clinical Trial Results for Lead Drug Candidate RLS-1496 in Patients with Plaque Psoriasis, Atopic Dermatitis, and Skin Aging26.3.2026 14:30:00 EET | Press release

Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced preliminary results from a single-center, ascending-dose, randomized, double-blind, vehicle-controlled trial in patients with plaque psoriasis, atopic dermatitis, and skin aging (photo-aged skin). The recently completed Phase 1 clinical trial, conducted in the European Union, was designed to assess the safety, tolerability, clinical effects, plasma bioavailability, and pharmacodynamics of topical RLS-1496—the first-ever GPX4 (selective glutathione peroxidase 4) modulator to be studied in human trials, and the first specifically targeting cellular rejuvenation, an area of great interest to the scientific community as a new therapeutic pathway. The study met its primary endpoint, with RLS-1496 also demonstrating early signs of efficacy. Preliminary Trial Results RLS-1496 was well-tolerated,

GE HealthCare announces lead industrial role in largest EU-funded IHI consortium to advance cardio-oncology care across Europe26.3.2026 14:30:00 EET | Press release

GE HealthCare (Nasdaq: GEHC) today announced its leading industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of cardiovascular risks in cancer patients across Europe. COMPASS combines clinical excellence with novel healthcare technology, and with a total budget of €50.5 million and more than sixty partners, it is one of the largest public-private partnerships under the IHI. Cardiovascular diseases are rising sharply among cancer patients and survivors, driven both by the increasing prevalence of pre‑existing cardiovascular conditions at diagnosis and by the expanding use of highly effective antitumor therapies - including chemotherapy, radiotherapy and targeted therapies - many of which are associated with cardiovascular toxicities. Global studiesi show that heart-related complications are now the second leading cause of death in cancer survivors, after the cancer itself, accounting for

Lone Star Funds Completes Acquisition of Alliance Ground International26.3.2026 14:30:00 EET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has completed the acquisition of Alliance Ground International (“AGI”), a leading North American airport services provider. “We are excited to partner with the AGI management team to drive the business forward,” said Donald Quintin, Chief Executive Officer of Lone Star. “The company has a superior service offering and a track record of success across its integrated operations. We see opportunities to continue to invest in the business and its people to continue to grow its capabilities and ensure it remains best-in-class in delivering for the aviation industry.” “Today marks an important next step for AGI as we move forward in partnership with Lone Star,” said Jared Azcuy, Chief Executive Officer of AGI. “Our commitment to safety, reliability, and operational service excellence remains unchanged. This partnership strengthens our ability to deliver for our airline partners and reinforces that the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye